

REVIEW ARTICLE

Antimicrobial peptides

MARTIN MALMSTEN

Department of Pharmacy, Uppsala University, Uppsala, Sweden

Abstract

With increasing antibiotics resistance, there is an urgent need for novel infection therapeutics. Since antimicrobial peptides provide opportunities for this, identification and optimization of such peptides have attracted much interest during recent years. Here, a brief overview of antimicrobial peptides is provided, with focus placed on how selected hydrophobic modifications of antimicrobial peptides can be employed to combat also more demanding pathogens, including multi-resistant strains, without conferring unacceptable toxicity.

Key words: *AMP, antimicrobial peptide, bacteria, liposome, membrane*

Introduction

Due to increasing antibiotic resistance, there is much current interest in novel therapeutic approaches, including antimicrobial peptides (AMPs) (1-3). AMPs are key components of the innate immune system, ≈10–40 amino-acids long, generally net positively charged, and containing a substantial fraction of hydrophobic residues. Although AMPs induce multiple damages in bacteria, including inhibition of DNA, RNA, and protein synthesis, their main mode of action is disruption of bacterial membranes (1-3). Several mechanisms for this have been suggested, including detergency-like packing disruption and formation of barrel-stave or toroidal pores (Figure 1) (1-5). Chemical potential gradients may also cause transient defects due to peptide translocation through the membrane (6). Furthermore, lateral membrane expansion due to peptide binding allows relaxation of the alkyl chains and causes membrane thinning, further facilitating membrane destabilization (7). Also peptide-induced lipid segregation and/or phase transition may contribute to peptide-induced membrane rupture (8).

Critical for the therapeutic application of AMP is that it is selective, efficiently disrupting bacteria and

other pathogens, but causing limited damage to human cell membranes. By careful selection of peptide properties, however, such selectivity is possible through composition differences between bacterial and human membranes. Thus, human cell membranes are rich in cholesterol (20–50 mol%) (9), while fungal membranes instead contain ergosterol, and bacteria no sterol at all. There are also differences in phospholipid composition. For example, the outer leaflet of erythrocyte membranes is dominated by zwitterionic lipids, including sphingomyelin and phosphatidylcholine, making it essentially uncharged (9), while bacteria membranes are rich in anionic lipids (10,11). Such composition differences contribute to differences in peptide binding and membrane destabilization (1-4).

Effects of peptide properties on membrane disruption

Peptide length

Due to the increased entropy penalty, per amino-acid, on adsorption, membrane binding is expected to decrease with decreasing peptide length. For similar reasons, there is also a decreased tendency to form

Correspondence: Martin Malmsten, Department of Pharmacy, Uppsala University, PO Box 580, SE-751 23 Uppsala, Sweden. Fax: +46 184714377.
E-mail: martin.malmsten@farmaci.uu.se

(Received 2 January 2014; accepted 25 February 2014)

ISSN 0300-9734 print/ISSN 2000-1967 online © 2014 Informa Healthcare
DOI: 10.3109/03009734.2014.899278




Figure 1. Schematic illustration of AMP interaction with lipid membranes. In barrel-stave pores, peptide oligomers organize in a trans-membrane structure, while toroidal pores are disorganized membrane defects caused by curvature strain. Higher peptide densities may subsequently cause complete membrane disintegration (micellization). Furthermore, peptide binding to the polar headgroup region allows relaxation of the alkyl chains and causes membrane thinning. In addition, chemical potential gradients may result in peptide translocation across the membrane. Finally, peptide-induced lipid segregation or phase separation may contribute to AMP-induced membrane rupture.

(amphiphilic) secondary structures with decreasing peptide length. Together, these effects are expected to result in decreased membrane lysis and antimicrobial effect with decreasing peptide length, as indeed generally found (12,13). Having said that, there may be room for *selective* truncations of longer AMPs without losing too much activity (depending on composition), in some cases even reaching improved performance of the truncated peptide (14). Ultimately, however, selective membrane-rupturing capacity is lost when AMPs become sufficiently short.

Peptide charge

Since bacterial membranes are anionic, peptide-induced lysis of bacterial membranes generally increases with peptide positive charge. For example, Ringstad et al. found membrane rupture by the C3a-derived peptide CNY21 to increase with peptide positive charge, but to be completely lost after removal of all positive charges in the peptide (15).

Through titrating histidine groups, AMPs may furthermore display pronounced pH-dependent charge, resulting in membrane lysis and antibacterial activity at acidic conditions (i.e. $\text{pH} < \text{pK}_a$), but abrogated antimicrobial activities above the pK_a of histidine (≈ 6.0 for an isolated H) (12). Also the charge distribution and nature of the charged group have been found to affect membrane interactions of AMPs (2).

Peptide secondary structure

Formation of amphiphilic ordered structures, particularly α -helices, has been found to correlate to peptide-induced membrane disruption (1-4). Illustrating this, GKE21 is an internal peptide sequence that maintains the bactericidal potency of LL-37, but displays lower toxicity (14). GKE21 forms a nearly perfectly amphiphilic helix, with polar/charged and hydrophobic/non-polar residues localized on opposite sides. Consequently, helix induction provides a




Figure 2. Combined hemolysis (A) and viable count (VCA), (B) assay for *S. aureus* and *P. aeruginosa* (both 2×10^8 cfu/mL) added to 50% citrate blood at peptide concentrations of 60 and 120 μ M (23).

driving force for membrane binding. Thus, reducing the helix-related amphiphilicity through selected D-amino-acid substitutions results in reduced membrane disruption and bacterial killing (16). In parallel, helix destabilization generally reduces cytotoxicity of AMPs, although such toxicity reduction may ultimately result in reduction or elimination of antimicrobial effects.

Peptide hydrophobicity

Due to electrostatic screening, highly charged and hydrophilic peptides lose much of their membrane-disrupting effect at high ionic strength (e.g. at physiological conditions). By increasing AMP hydrophobicity, such inactivation can be avoided (1-3,17). For very hydrophobic peptides, however, binding occurs irrespectively of membrane composition. This, in turn, results in lysis of both bacteria and human cells. For example, hydrophobic K/L peptides are even more hemolytic than the bee venom melittin (18). Thus, AMP hydrophobicity can only be moderately increased to boost peptide potency without losing selectivity and inducing toxicity.

End-tagging with hydrophobic amino-acids

In analogy to hydrophobic point mutations, hydrophobic end-modifications promote membrane binding and antimicrobial activity of AMPs, increasing with the length of the hydrophobic moiety (19,20). Due to their long acyl chains, commonly investigated lipopeptides (including therapeutically used ones) are exceedingly efficient in their ability to insert into lipid membranes, essentially independent of the composition of the latter (21). Such lipopeptides therefore display substantial toxicity, which has restricted their use to local applications, and to severe indications for which other antibiotics are ineffective, e.g. multi-resistant *Pseudomonas aeruginosa* infections in cystic fibrosis (19). Alternatively, however, end-tagging with hydrophobic amino-acid stretches (notably W and F) offers an approach to achieve high, but *selective*, AMP activity (22). Demonstrating this, Figure 2 shows antimicrobial and cell toxicity data for the peptide GRR10W5N, displaying potent broad-spectrum antimicrobial effects, also at physiological ionic strength (23,24). At the same time, however, toxicity to human cells is limited. This pronounced selectivity can be understood as follows: For a peptide to be able to




Figure 3. (A) Peptide-induced liposome leakage for GRR10W4N at 10 mM Tris, pH 7.4. Shown in (B) and (C) is the adsorption of the same peptide to supported lipid bilayers, as well as the change in surface pressure ($\Delta\Pi$) due to insertion of GRR10W4N to zwitterionic DOPC and DOPC/cholesterol, and anionic DOPE/DOPG monolayers from Tris buffer, pH 7.4 (23).

insert, it must overcome the cohesive energy of the membrane. Particularly for bulky groups such as W and F, which require substantial area expansion, insertion into membranes containing cholesterol (known to condense lipid bilayers (25)) is precluded. This difference in membrane interactions in the presence and absence of cholesterol, and that due to the charge difference between anionic and zwitterionic membranes, contributes to the pronounced selectivity between bacteria and human cells (Figure 3) (23).

For reasons of cost and stability, reducing peptide length is of major importance in the development of

AMPs towards novel therapeutics. Here, W/F-tagging offers opportunities for efficient and selective ultra-short AMPs, allowing potency and salt resistance to be maintained down to 4–7 amino-acids in the hydrophilic template peptide (26). Short W-tagged peptides furthermore offer opportunities to combat difficult pathogens. Demonstrating this, the peptide RRPRPRPW-NH₂ was found to be effective against a range of ‘superbugs’, including methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci, and multi-drug resistant *P. aeruginosa*, yet displaying very limited toxicity (24).

Resistance issues of AMPs

Particularly in early literature, microbes were speculated to be unable to develop resistance towards AMPs. More recently, however, a number of resistance mechanisms have been reported, including upregulation of proteolytic enzymes able to degrade AMPs, membrane modifications resulting in decreased negative potential of bacterial membranes, and release of glucose aminoglycans (GAGs), polysaccharides, and other polyanionic species able to scavenge AMPs (27). For example, *S. aureus* can resist various AMPs by reducing its net membrane charge through introduction of cationic moieties (28). Similarly, *Serratia* sp. and *Morganella* sp. have an outer membrane lacking acidic lipids (29), while *Shigella* sp. releases plasmid DNA, inactivating AMPs by scavenging. In an alternative strategy, *Streptococcus pyogenes*, *Pseudomonas* spp., *S. aureus*, *Staphylococcus epidermidis*, and *Porphyromonas gingivalis* produce AMP-degrading proteases. In addition, *Pseudomonas* spp., *Enterococcus faecalis*, and *S. pyogenes* degrade host macromolecules, including GAGs and collagen, so that the degradation products can scavenge AMPs (2). More relevant than the occurrence of mutations as such, however, are consequences thereof on bacteria viability and fitness. For example, mutations in the putative transport protein SbmA have been shown to be responsible for the resistance of *Salmonella enterica* against PR-39. Importantly, *sbmA* mutants were found to be as fit as the wild type regarding growth and survivability (30), while investigations with protamine demonstrated the corresponding mutants to display drastically reduced fitness and growth (31). Reduced fitness was observed also for mutants against LL-37, CNY100HL, and wheat germ histones (32). Important from a 'resistance spread' perspective, the PR-39 mutants display similar susceptibility as the wild type to different types of antibiotics and AMPs (30), while protamine mutants were less susceptible than the parental strain to several other antimicrobials, including colistin, gentamicin, lactoferrin, and human defensin HNP-1 (31). Further work on these important aspects is, however, needed. Furthermore, despite having been convincingly demonstrated *in vitro*, resistance development to AMPs *in vivo* needs to be further clarified, since conditions experienced by bacteria in a laboratory setting are likely to differ from those *in vivo*. In the latter case, the microbes are exposed to a cocktail of AMPs, which may reduce or alter the selection pressure underlying resistance development. Furthermore, microbes are not continuously exposed to the same specific stress, as they encounter different AMPs within the host

tissue and species. It remains of major importance, however, to clarify whether, and under what circumstances, resistance to antimicrobial peptides can develop to provide cross-resistance to AMPs, and provide AMP-resistant mutants with a competitive advantage also *in vivo*.

Summary

AMPs affect bacteria in numerous ways, but their main mode of action is the disruption of bacterial membranes. Peptide length, charge, secondary structure, and hydrophobicity all influence AMP-membrane interactions. Contrary to hydrophobic point mutations and acyl modifications, end-tagging with W and F stretches allows AMP potency to be boosted without causing unacceptable toxicity effects. Such W/F-tagged peptides are efficient against a wide spectrum of micro-organisms, including various 'superbugs'. Particularly for AMPs not sensitive to infection-related proteolysis, this also opens up applications characterized by high proteolytic activity, such as infected wounds, eye infections, and cystic fibrosis.

Acknowledgements

This work was financed by the Swedish Research Council.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

1. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Micro.* 2005;3:238–50.
2. Pasupuleti M, Schmidtchen A, Malmsten M. Antimicrobial peptides: key components of the innate immune system. *Crit Rev Biotechnol.* 2012;32:143–71.
3. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol.* 2006;24:1551–7.
4. Shai Y. Mode of action of membrane active antimicrobial peptides. *Biopolymers.* 2002;66:236–48.
5. Melo MN, Ferre R, Castanho RMA. Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. *Nat Rev Micro.* 2009;7:245–50.
6. Pokorny A, Almeida PFF. Kinetics of dye efflux and lipid flip-flop induced by d-lysine in phospholipid vesicles and the mechanism of graded release by amphipathic α -helical peptides. *Biochemistry.* 2004;43:8846–57.
7. Mecke A, Lee DK, Ramamoorthy A, Orr BG, Banaszak Holl MM. Membrane thinning due to antimicrobial peptide binding: an atomic force microscopy study of MSI-78 in lipid bilayers. *Biophys J.* 2005;89:4043–50.

8. El Jastimi R, Lafleur M. Nisin promotes the formation of non-lamellar inverted phases in unsaturated phosphatidylethanolamines. *Biochim Biophys Acta*. 1999;1418:97–105.
9. Boesze-Battaglia K, Schimmel RJ. Cell membrane lipid composition and distribution: implications for cell function and lessons learned from photoreceptors and platelets. *J Exp Biol*. 1997;200:2927–36.
10. Lugtenberg EJJ, Peters R. Distribution of lipids in cytoplasmic and outer membranes of *Escherichia coli* K12. *Biochim Biophys Acta*. 1976;441:38–47.
11. Haest CW, de Gier J, den Kamp JA, Bartels P, van Deenen LL. Changes in permeability of *Staphylococcus aureus* and derived liposomes with varying lipid composition. *Biochim Biophys Acta*. 1972;255:720–33.
12. Ringstad L, Schmidtchen A, Malmsten M. Effect of peptide length on the interaction between consensus peptides and DOPC/DOPA bilayers. *Langmuir*. 2006;22:5042–50.
13. Deslouches B, Phadke SM, Lazarevic V, Cascio M, Islam K, Montelaro RC, et al. De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. *Antimicrob Agents Chemother*. 2005;49:316–22.
14. Sigurdardottir T, Andersson P, Davoudi M, Malmsten M, Schmidtchen A, Bodelsson M. In silico identification and biological evaluation of antimicrobial peptides based on human cathelicidin LL-37. *Antimicrob Agents Chemother*. 2006;50:2983–9.
15. Ringstad L, Andersson Nordahl E, Schmidtchen A, Malmsten M. Composition effect on peptide interaction with lipids and bacteria: variants of C3a peptide CNY21. *Biophys J*. 2007;92:87–98.
16. Strömstedt AA, Pasupuleti M, Schmidtchen A, Malmsten M. Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. *Antimicrob Agents Chemother*. 2009;53:593–602.
17. Ringstad L, Protopapa E, Lindholm-Sethson B, Schmidtchen A, Nelson A, Malmsten M. An electrochemical study into the interaction between complement-derived peptides and DOPC mono- and bilayers. *Langmuir*. 2008;24:208–16.
18. Cornut I, Büttner K, Dasseaux JL, Dufourcq J. The amphipathic α -helix concept: application to the de novo design of ideally amphipathic Leu, Lys peptides with hemolytic activity higher than melittin. *FEBS Letts*. 1994;349:29–33.
19. Jerala R. Synthetic lipopeptides: a novel class of anti-infectives. *Expert Opin Investig Drugs*. 2007;16:1159–69.
20. Avrahami D, Shai Y. Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. *Biochemistry*. 2002;41:2254–63.
21. Eeman M, Francius G, Dufren YF, Nott K, Paquot M, Deleu M. Effect of cholesterol and fatty acids on the molecular interactions of fengycin with stratum corneum mimicking lipid monolayers. *Langmuir*. 2009;25:3029–39.
22. Schmidtchen A, Pasupuleti M, Mörgelin M, Davoudi M, Alenfall J, Chalupka A, et al. Boosting antimicrobial peptides by hydrophobic oligopeptide end-tags. *J Biol Chem*. 2009;284:17584–94.
23. Schmidtchen A, Ringstad L, Kasetty G, Mizuno H, Rutland MW, Malmsten M. Membrane selectivity by W-tagging of antimicrobial peptides. *Biochim Biophys Acta*. 2011;1808:1081–91.
24. Malmsten M, Kasetty G, Pasupuleti M, Alenfall J, Schmidtchen A. Highly selective end-tagged antimicrobial peptides derived from PRELP. *PLoS One*. 2011;6:e16400.
25. Mouritsen OG, Zuckermann MJ. What's so special about cholesterol? *Lipids*. 2004;39:1101–13.
26. Pasupuleti M, Schmidtchen A, Chalupka A, Ringstad L, Malmsten M. End-tagging of ultra-short antimicrobial peptides by W/F stretches to facilitate bacterial killing. *PLoS One*. 2009;4:e5285.
27. Nizet V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. *Curr Issues Mol Biol*. 2006;8:11–26.
28. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, et al. *Staphylococcus aureus* resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. *J Exp Med*. 2001;193:1067–76.
29. Giuliani A, Pirri G, Nicoletto SF. Antimicrobial peptides: an overview of a promising class of therapeutics. *Cent Eur J Biol*. 2007;2:1–33.
30. Pranting M, Negrea A, Rhen M, Andersson DI. Mechanism and fitness costs of PR-39 resistance in *Salmonella enterica* serovar Typhimurium LT2. *Antimicrob Agents Chemother*. 2008;52:2734–41.
31. Pranting M, Andersson DI. Mechanisms and physiological effects of protamine resistance in *Salmonella enterica* serovar Typhimurium LT2. *J Antimicrob Chemother*. 2010;65:876–87.
32. Lofton H, Pranting M, Thulin E, Andersson DI. Mechanism and fitness costs of resistance to antimicrobial peptides LL-37, CNY100HL and wheat germ histones. *PLoS One*. 2013;8:e68875.